Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI)

Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: d26b383bd4d7a92eecda7d760db49718bfa9c753
First added on: Feb 18, 2025